Rheumatoid arthritis: Timely diagnosis and early treatment initiation are key determinants of prognosis

by Medical University of Vienna

edited by Swati Mestri, reviewed by Andrew Zinin

Swati Mestri

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

Early, consistently managed treatment can have a decisive impact on the course of rheumatoid arthritis and prevent permanent joint damage. An international review led by Josef S. Smolen of the Medical University of Vienna highlights, based on current research, which diagnostic and therapeutic measures are crucial for a good outcome in patients with this disease.

The analysis, published in JAMA, summarizes the evidence on the etiology, diagnosis, treatment and prognosis of the disease.

For the review, the research team from the Medical University of Vienna and Stanford University (U.S.) screened 15,886 scientific publications. Following a detailed assessment of 620 papers, 120 studies were included in the analysis, comprising 43 randomized clinical trials, 28 cohort studies, 11 systematic reviews and meta-analyses, as well as 15 international guidelines and recommendations for clinical practice.

The results show that the timing of diagnosis is crucial for the course of the disease. If the condition is detected, ideally within six weeks of the onset of the first symptoms, treatment with disease-modifying antirheumatic drugs (DMARDs) can be started early and be particularly successful. These DMARDs suppress inflammation and can prevent joint damage and further progression of the disease.

Clear treatment target, consistent adjustment of treatment

"The aim of treatment is to achieve at least a 50% reduction in disease activity within three months, as well as remission—that is, being symptom-free—or at least low disease activity after six months," explains study lead Josef S. Smolen (Division of Rheumatology, Department of Medicine III, MedUni Vienna).

As first-line therapy, current European recommendations propose the drug methotrexate, ideally supplemented by a temporary course of glucocorticoids. Around 40% of patients achieve the primary treatment goal of remission within six months with this therapeutic approach.

If this target is not achieved, the addition of biological agents or Janus kinase inhibitors (JAK inhibitors)—drugs that interfere with specific cells, molecules or signaling pathways of the immune system—increases the proportion of patients in remission or with low disease activity to around 80% over the course of the disease.

The study authors also emphasize the importance of the so-called "treat-to-target" approach. This involves regularly monitoring disease activity using standardized measurement tools and adjusting treatment early if necessary. This structured approach has been shown to improve treatment outcomes compared with routine care without defined treatment targets.

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks the synovial membrane. The resulting inflammation can cause permanent damage to cartilage and bone and lead to lasting functional limitations.

"The scientific evidence now clearly shows that an early diagnosis, a clearly defined treatment target and consistent adjustment of treatment create the best conditions for preventing joint damage and maintaining patients' quality of life in the long term," says co-author Daniel Aletaha, head of the Division of Rheumatology at MedUni Vienna.

Publication details

Josef S. Smolen et al, Rheumatoid Arthritis in Adults, JAMA (2026). DOI: 10.1001/jama.2026.15455

Journal information: Journal of the American Medical Association

Key medical concepts

Rheumatoid ArthritisMethotrexateJanus Kinase Inhibitors

Clinical categories

RheumatologyCommon illnesses & Prevention Provided by Medical University of Vienna Who's behind this story?

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Rheumatoid arthritis: Timely diagnosis and early treatment initiation are key determinants of prognosis (2026, September 11) retrieved 12 September 2026 from https://medicalxpress.com/news/2026-09-rheumatoid-arthritis-diagnosis-early-treatment.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.